论文部分内容阅读
目的探讨瑞舒伐他汀治疗慢性心力衰竭的疗效及对内皮素及炎性因子的影响。方法慢性心力衰竭患者98例采用随机数字表法分为观察组和对照组两组,各49例,对照组患者采用常规对症治疗,观察组患者在常规对症治疗的基础上加用瑞舒伐他汀治疗,比较两组患者治疗前后心功能、血浆内皮素等炎性因子水平及血管内皮细胞功能变化情况。结果所有患者治疗前,各指标水平差异无统计学意义(P>0.05),治疗后,两组患者左心室射血分数(LVEF)明显升高,且观察组明显高于对照组(P<0.05),两组患者左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室舒张末容积(LVEDV)、左心室收缩末容积(LVESV)等指标水平较治疗前明显降低(P<0.05),且观察组明显低于同期对照组(P<0.05)。治疗后两组患者的血浆内皮素、白介素6(IL-6)、白介素23(IL-23)及肿瘤坏死因子-α(TNF-α)等炎性因子水平明显降低(P<0.05),且观察组患者各指标水平明显高于同期对照组,具有统计学意义(P<0.05)。观察组患者治疗后静脉血一氧化氮(NO)水平明显低于对照组(P<0.05),而静脉血内皮素-1(ET-1)、血浆α-颗粒膜蛋白(GMP-140)、血管性假血友病因子(VWF)水平则明显高于对照组,差异具有统计学意义(P<0.05)。结论瑞舒伐他汀可有效降低慢性心力衰竭患者血浆内皮素和炎性因子水平,有效扩充患者心室容积,明显改善心室射血功能和血管内皮细胞功能。
Objective To investigate the therapeutic effect of rosuvastatin on chronic heart failure and its effect on endothelin and inflammatory cytokines. Methods A total of 98 patients with chronic heart failure were randomly divided into observation group and control group with 49 cases in each group. Patients in the control group were treated with conventional symptomatic treatment. Patients in the observation group were treated with rosuvastatin The changes of cardiac function, plasma endothelin and other inflammatory factors and the changes of endothelial cell function were compared between the two groups before and after treatment. Results Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, left ventricular ejection fraction (LVEF) was significantly increased in both groups, and the observation group was significantly higher than the control group (P <0.05 ), LVEDD, LVESD, LVEDV and LVESV in both groups were significantly lower than those before treatment (P <0.05), and the observation group was significantly lower than the control group (P <0.05). After treatment, the levels of plasma endothelin, interleukin 6 (IL-6), interleukin 23 (IL-23) and tumor necrosis factor-α (TNF-α) were significantly decreased (P <0.05) The level of each index in the observation group was significantly higher than that in the control group at the same period, with statistical significance (P <0.05). The level of NO in the observation group was significantly lower than that in the control group (P <0.05), while the levels of ET-1, GMP-140, VWF was significantly higher than that of the control group (P <0.05). Conclusion Rosuvastatin can effectively reduce the levels of plasma endothelin and inflammatory cytokines in patients with chronic heart failure, and effectively expand the ventricular volume in patients with ventricular ejection, significantly improve the ventricular ejection function and vascular endothelial cell function.